Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia

J R Coll Physicians Edinb. 2011 Jun;41(2):117-8. doi: 10.4997/JRCPE.2011.204.

Abstract

Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with this therapy, in particular heart rhythm disorders due to QT interval prolongation. We present a case of ventricular arrhythmia with no QT prolongation in a patient receiving arsenic trioxide therapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Arrhythmia Agents / therapeutic use*
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Arsenic Trioxide
  • Arsenicals / adverse effects*
  • Arsenicals / therapeutic use
  • Electrocardiography
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Magnesium / therapeutic use
  • Manitoba
  • Metoprolol / therapeutic use
  • Oxides / adverse effects*
  • Oxides / therapeutic use
  • Potassium / therapeutic use
  • Tachycardia, Ventricular / chemically induced*
  • Tachycardia, Ventricular / diagnosis
  • Tachycardia, Ventricular / drug therapy*

Substances

  • Anti-Arrhythmia Agents
  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • Metoprolol
  • Magnesium
  • Potassium
  • Arsenic Trioxide